n INTRODUCTION T he mechanisms causing most autoimmune diseases (AID) are still unknown. Genetic factors are surely involved but, although genes and genetic loci causing predisposition to autoimmunity are being identified, there are evidences demonstrating that non-genetic factors, including several epigenetic deregulations, also contribute to autoimmune etiologies. At this regard several reviews, pointing the attention to the epigenetic involvement in the pathogenesis of autoimmune disorders, have recently been published (1) (2) (3) (4) . Epigenetics is referred to as stable and heritable changes in gene expression that are not accompanied by alterations in DNA sequence. In fact, eukaryotic gene expression requires the regulated activity of transcription factors, but also transcriptional epigenetic mechanisms. Only by studying epigenetic mechanisms it has been possible to explain, at least in part, how cells with the same DNA can differentiate into different cell types and how a phenotype can be passed from one cell to its daughter cells. It is also well known that epigenetic mechanisms are important for controlling the pattern of gene expression during development, the cell cycle, and the response to biological or environmental changes. It is also essential to note that epigenetic regulation is a reversible phenomenon and that, unlike genetic alterations, which are permanent and affect all cells, epigenetic modifications are cell type specific. In addition, several recent studies have demonstrated that disrupting the epigenetic regulation of transcription plays crucial roles in the development of autoimmune diseases. In the present review a description of the most frequent epigenetic deregulations found in rheumatic autoimmune disorders will be analyzed.
n EPIGENETIC REGULATION
Epigenetic regulatory mechanisms comprise DNA methylation, a variety of histone modifications, and microRNA activity, all of which act upon gene and protein expression levels (1) (2) (3) . DNA methylation is defined as the postsynthetic addition of methyl groups to cytosine bases, catalyzed by a DNA methyltransferase (DNMT). Interestingly, DNA M. Galeazzi, E. Balistreri, C. Giannitti, et al. review methylation leads to gene silencing and may also interfere with the binding of some transcription factors (5, 6) . Histone modifications regulate gene expression by changing the degree to which gene loci are accessible to transcription machinery. The N-terminal tail of histones protrudes from nucleosomal core particles and is subject to an array of post-translational modifications (7). These modifications include, but are not limited to, acetylation, methylation, phosphorylation, ADP-ribosylation, sumoylation and ubiquitination. MicroRNAs (miRNAs), the main focus of the present review, are small noncoding RNAs that negatively regulate translation and stability of several hundreds messenger RNAs (mRNAs). In the last years many efforts have been dedicated to the identification of cellular processes that are epigenetically deregulated, as they could contribute to our knowledge of the diseases. The current state-of-the-art of epigenetics in AID has revealed different profiles according to the disease (1). In particular, alterations in genomic DNA methylation and histone modifications have been implicated in the pathogenesis of systemic lupus erythematosus (SLE), while it has been reported that histone acetylation pattern is affected in rheumatoid arthritis (RA) and the abnormal expression of retroviral elements, from the epigenetically silenced endogenous retrovirus HERV-W, has been associated with the evolution and prognosis of the disease in multiple sclerosis (MS). Furthermore, considering the cell type specificity of epigenetic modification, it has been clearly demonstrated that in SLE both CD4+ T and B cells show an altered pattern of DNA methylation and histone acetylation (8) (9) (10) , while lymphocytes and synovial fibroblasts have been found to be hypomethylated in RA (11) ; on the other hand, DNA was found to be methylated in lymphocytes and skin fibroblasts of patients with systemic sclerosis (SSc). There are also evidences that a defective DNA methylation can be found in brain cells of MS patients (3) . Thus, considering the tight relationship between environmental factors and epigenetic mechanisms, it is not surprising that several reports have linked epigenetic dysregulations with both idiopathic AID and chemical/drug-induced AID. This mechanism is probably involved in drug, induced SLE where demethylating drugs such as 5-azacytidine (5-aza), procainamide and hydralazine, can also induce lupus-like autoimmunity, both in vitro and in vivo (8, 12 ). An additional important deregulating epigenetic mechanism, the ageing, can give an attractive explanation for agerelated AID. Indeed, there are evidences that monozygotic twins are epigenetically indistinguishable early in life but, with age, exhibit substantial differences especially when they have led different lifestyles and have spent less of their lives together (13) . Moreover, several studies have underlined the topic role of X-chromosome inactivation in predisposing women to autoimmunity and neoplasia (4). All the abovementioned findings have also led to the development of epigenetic therapies that are being evaluated (14, 15) . Several Authors have found associations between epigenetic histone modifications and disease progression with autoantibody (Abs) production, suggesting that these Abs may be used as biomarkers. In Table I we report specific epigenetic defects that have been found associated with autoantibody production in several autoimmune disorders.
Involvement of MicroRNAs in autoimmune diseases
MicroRNAs (miRNAs) are small noncoding RNAs, about 22 nucleotides long, found in plants and animals, which have emerged as a major class of regulatory genes during development and cell differentiation (33) . Their involvement in autoimmunity has been recently reviewed by Carissimi et al. (34) . MiRNAs are produced from a long primary transcript, through a series of endonucleolytic maturation steps. In the canonical pathway they are transcribed by RNA polymerase II as long primary miRNA (pri-miRNA) transcripts, which are cleaved by the nuclear-specific multiprotein complex comprised of the RNase III enzyme Drosha (35, 36) liberating an approximately 60-to-80-nucleotide precursor (pre-miRNA) (37) . In the cytoplasm the pre-miRNA is further processed by the RNase III enzyme, Dicer, to a doublestranded miRNA that is ~21 nucleotides long (38) . Only one strand of the miRNA duplex is subsequently incorporated into a ribonuclear particle (RNP) complex, the RNA-induced silencing complex (RISC), whose catalytic component is a member of the Argonaute family (Ago1-4) (39). Bioinformatic approaches and molecular cloning have identified hundreds of miRNAs in plants, animals and viruses (40) . Target predictions support a view in which each miRNA negatively regulates translation and stability of several hundreds messenger RNAs (mRNAs) (41-43). These regulations are exerted through inhibition of individual key targets, fine-tuning of target function and a coordinated regulation of multiple targets. These discoveries confirm that this class of small non-coding RNA molecules represents a novel level of regulatory control over gene expression programs in several organisms (33) . MiRNAs display distinct temporal and spatial expression patterns and are key players in a wide variety of physiological processes such as haematopoiesis, proliferation, tissue differentiation, cell type identity maintenance, apoptosis, signal transduction and organ development (44) . The analysis of miRNAs expression and function during haematopoietic lineages development has shed light on complex regulatory mechanisms where miRNAs fine-tune immune system cell differentiation and function. There is evidence that individual miRNAs play a critical role in B and T cell homeostasis and response (45) (46) (47) , and that T cell selection in the thymus is controlled by a particular miRNA (48) . Furthermore, the fact that miRNAs are involved in the modulation of T cell selection, T cell receptor sensitivity as well as Treg cell development in normal immune response, as also demonstrated in animal models (49) (50) (51) (52) (53) , suggests that these molecules may also be involved in the development of inflammatory or autoimmune diseases. In addition, the pioneer knock out of miR-155 in mice revealed an essential role in the acquired immunity for this miRNA. miR-223 expression is thought to be confined to the myeloid lineage according to most reports. Nevertheless, the role of this miRNA in lymphocytes has not been further investigated thus far. Our study also showed that miR-223 is preferentially expressed in CD4+ T lymphocytes and this expression is independent of treatment, suggesting that it is a feature associated to the disease rather than a consequence of therapy. We recently confirmed these results in a group of patients with early RA (59) . On the basis of these observations, we speculate that this aberrant over-expression of miR-223 in RA T-lymphocytes could contribute to the pathogenesis of the disease. Identification of miR-223 targets in T-lymphocytes could therefore contribute to elucidate some of the molecular mechanisms that lead to RA. In Table II miRNAs found to be associated with RA, as well as their targets and target's function, are reported. (73) .
MicroRNAs in systemic lupus erythematosus
As the introduction of miR-125a into lupus T cells alleviated the elevated RANTES expression, these findings extend the role of miRNAs in the pathogenesis of lupus but also provide potential strategies for therapeutic intervention. Further studies examining larger patient cohorts and different patient populations are needed to determine if the differential expression of these miRNAs in SLE are reproducible. Dicer can become target of autoimmunity giving rise to various types of immunological disorders including autoimmune ones, often in cooperation with viral infections (74) (Table III) .
MicroRNAs in Sjögren syndrome
Very recently, in a pilot study, Alevizos et al. (75) showed that miRNAs expression profiles can separate glands of primary Sjögren syndrome (pSS) patients from controls and can distinguish subsets of pSS patients with low or high-grade inflammation. Interestingly, in half of the patients with a focus score of 12, the miR-17-92
cluster, which has been associated with specific types of lymphocytes and lymphocytic pathologies, was downregulated. Authors have also identified two miRNAs with an opposite relationship to inflammation: one increased and the other decreased between the low and high focus score groups. Michael et al. explored the presence of miRNAs in exosomes isolated from parotid and submandibular saliva showing a striking difference between miRNAs profile in saliva obtained from patients and healthy donors (76). Lu et al. have recently showed that two miRNAs (-574 and -768-3p) are overexpressed in the salivary glands of pSS patients. They reported that these two suspected epithelial cell miRNAs could be used to predict the evolution of the disease. The same authors reported data obtained from their studies of non-obese diabetic (NOD) mice (B6DC) that develop a disease similar to human pSS. They highlighted two miRNAs, -150 and -146, that are upregulated in target tissues and in PBMCs of B6DC mice compared to control mice. The same authors have also reported that miRNA-146a expression is increased in PBMCs and salivary glands of pSS patients (1) ( Table IV) .
MicroRNAs in systemic sclerosis (SSc)
SSc is a multi-systemic fibrotic disorder associated with high morbidity and mortality. The role of miRNAs in this disease, Table V) . 
review n CONCLUSIONS
It is now well established that epigenetic mechanisms are important in the control of the pattern of gene expression during the development, the cell cycle, and in response to biological or environmental changes (81) . Epigenetic regulatory mechanisms comprise DNA methylation, histone acetylation, and microRNA activity, and dysregulations of each of them can be involved in autoimmune disorders. Several studies demonstrated that miRNAs expression is altered in systemic autoimmune diseases such as RA (82), SLE, pSS and SSc. Next critical steps are to identify the targets of these miRNAs and to determine the mechanisms by which miRNAs regulation/dysregulation contribute to the pathogenesis of these diseases. Some progress has been made, for example it is known that miR-155 can target MMP-3, which could potentially modulate tissue damage, and miR-146a can target TRAF6/IRAK-1 that should suppress inflammatory cytokine production. The first practical aspect of these discoveries is the suppression of arthritis in an animal model by inhibiting the expression of miRNAs-155. This result open the way for future utilization of miRNAs; in fact, further studies are also needed to elucidate if miRNAs could serve as useful disease markers or therapeutic targets. New information is emerging on new therapeutic opportunities (83, 84) . The usage of miRNAs as diagnostic tool will be facilitated by the possibility of detecting these molecules in blood serum or plasma. In fact, it has been already observed that particular patterns of circulating miRNAs can be detected at different expression levels in serum of cancer patients compared to healthy controls (85) . These observations prompted the hypothesis that circulating miRNAs could constitute a new class of serological biomarkers for several pathologies, including cancer and autoimmune diseases. Whilst our current knowledge of epigenetic processes is limited, the epigenomics will undoubtedly serve as a tool for diagnosis, prognosis, and therapy in the future.
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